Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.43 USD
Change Today +0.053 / 14.25%
Volume 2.1M
AVXL On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Open
$0.39
Previous Close
$0.37
Day High
$0.43
Day Low
$0.38
52 Week High
04/21/15 - $0.47
52 Week Low
12/1/14 - $0.15
Market Cap
32.8M
Average Volume 10 Days
1.3M
EPS TTM
$-0.29
Shares Outstanding
77.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANAVEX LIFE SCIENCES CORP (AVXL)

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.

4 Employees
Last Reported Date: 03/25/15
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $640.0K
Compensation as of Fiscal Year 2014.

anavex life sciences corp (AVXL) Key Developments

Anavex Life Sciences Corp. Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference

Anavex Life Sciences Corp. revealed full preclinical anti-seizure data for its lead drug candidate, ANAVEX 2-73, in a presentation on May 15, 2015 at the Antiepileptic Drug Trials XIII Conference. ANAVEX 2-73 demonstrated convincing data in three well-established and according to experts highly predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs. The cognitive-enhancing features of ANAVEX 2-73 might be a differentiating factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications. The strong performance of ANAVEX 2-73 was also confirmed in combination with three generations of epilepsy drugs currently on the market. ANAVEX 2-73 exhibited dose-dependent significant anti-convulsive action by providing almost complete to complete protection from tonic seizures in three established seizure models: In maximum electroshock (MES)-induced convulsions, 30 mg/kg ANAVEX 2-73 provided 90% protection. In pentylenetetrazol (PTZ)-induced convulsions, the same dose provided 85% protection. In a semicarbazide (SCZ) model, the same dose was able to delay the tonic seizures from 56.9 seconds to 99.2 seconds. In (PTZ)-induced convulsions, 60 mg/kg ANAVEX 2-73 had a long-lasting effect with 100% seizure protection after both 4 and 6 hours, respectively.

Anavex Life Sciences Corp. Reports Consolidated Financial Results for the Second Quarter and Six Months Ended March 31, 2015

Anavex Life Sciences Corp. reported consolidated financial results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported operating loss of $858,339 against $1,021,167 a year ago. Net loss was $1,724,859 or $0.03 per basic and diluted share against $1,018,860 or $0.03 per basic and diluted share a year ago. For six months, the company reported operating loss of $1,629,017 against $1,330,775 a year ago. Net loss was $2,511,577 or $0.05 per diluted share against $660,223 or $0.04 per diluted share a year ago.

Anavex Life Sciences Corp. Appoints Christopher Missling as Director

Anavex Life Sciences Corp. elected Christopher Missling as director for terms until the next annual meeting of stockholders or until each such director’s successor shall have been duly elected and qualified.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.43 USD +0.053

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies
 

Industry Analysis

AVXL

Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit www.anavex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.